Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibodutant in Female Patients With IBS-D (IRIS-3)
NCT02107196Phase 3Completed
- Sponsor
- Menarini Group
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing Ibodutant 10 mg with Placebo (2 arms). Primary endpoint: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment. Started Mar 2014; status: completed.
02
Drugs
ibodutant
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT02107196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107196.